Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
about
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trialIntravenous ω-3 Fatty Acids Plus Gemcitabine.Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patientsImpact of response shift on time to deterioration in quality of life scores in breast cancer patients.Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE)Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial.Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract.Parenteral nutrition at the palliative phase of advanced cancer: the ALIM-K study protocol for a randomized controlled trial.Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study.Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer.Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.Health-related quality of life in cancer patients at the end of life, translation, validation, and longitudinal analysis of specific tools: study protocol for a randomized controlled trial.Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III TrialConstruction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial.An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Study): study protocol for a randomized controlled trialImpact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time.Evaluation of quality of life following placement of self-expanding plastic stents as a bridge to surgery in patients receiving neoadjuvant therapy for esophageal cancer.Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials.How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial.Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).Statistical challenges of quality of life and cancer: new avenues for future research.Minimal clinically important differences in quality of life scores of oral cavity and oropharynx cancer patients.A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
P2860
Q30315797-65C6EFB6-AB5E-4F6A-931A-AFE02EF20F1FQ30667879-18D4E728-FDEB-4A26-8CAA-34E603A8186EQ33424793-DE32DCB5-AB12-417E-BCB7-0B794E93B376Q33590470-D9EE723C-3481-4C2D-8BBB-5048DBA48EBBQ33610112-D0BF5A89-C13B-4D04-833E-4A4E591922CDQ33901450-010E657D-7A86-43B0-9BD9-BF7363024A67Q33969006-7903CDF3-F94E-4F01-958D-596AF20C653BQ34404088-DFC205FB-17CB-4204-B7C7-A3690DFB5E0EQ34587250-18ADEB8F-9EA4-48A2-9949-59B78F9101C6Q34807981-CCA5CF81-88E2-4677-829A-3658327FB44AQ35079333-2616B0DD-C08E-4DB3-9711-AC3DC1E8FB76Q35584360-D68DD553-1298-4D79-9386-26A99EB6997DQ35641643-FCD07773-15CE-4A0C-A7D1-E4180DA6EC29Q35682543-A3CC0958-7F77-492D-93F0-E50240CE9C4CQ35711157-9A2E2525-82E1-4199-A163-0340114460ADQ35951026-8FEFE60D-2242-45BA-A01B-7DA497392EF2Q36054226-A366E2BE-42C8-4C3F-A2AA-7DB1C41AB3E2Q36082095-4324040E-D95E-4475-AACC-E20B82D9FC06Q36210646-2BC78BC2-26B4-4F05-A2CD-0F5BFF9ABBD8Q37063738-DDF5BE1C-B538-4033-8744-A104F61D3394Q37436377-FFDA5007-1477-444E-A0B6-8A2586D7369BQ37470535-05197A1F-753C-4952-BABA-895ED2E7630BQ37644538-EEDCA0FD-4AE3-4157-8690-C914EA20D1D3Q37940562-33BB9D15-21FF-4289-985A-D20BD811CE78Q38826639-A55AC2DE-F890-4909-9B0C-A7208455C8B3Q40195435-8DF34A4C-850B-4BF8-B1F3-04118E72143FQ41541911-93DB6CDC-0954-4289-B47D-E6164BF40936Q45267073-B3CFEE77-1763-4EAB-9FC5-81F00D229B10Q48080594-C75C2907-EF93-4F03-86DE-068DE8D51F66Q55431025-9D8BA499-DF35-465D-A83E-51A2600C2438
P2860
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@en
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@nl
type
label
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@en
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@nl
prefLabel
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@en
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@nl
P2093
P1476
Time until definitive quality ...... tic pancreatic adenocarcinoma.
@en
P2093
Emilie Maillard
Emmanuel Mitry
Franck Bonnetain
Jean-François Seitz
Jean-Louis Legoux
Laetitia Dahan
Laurent Bedenne
Philippe Rougier
P304
P356
10.1016/J.EJCA.2010.07.023
P577
2010-08-17T00:00:00Z